Table 1.
Baseline characteristics of the 600 study patients.
| Characteristic | All patients | Cisplatin + ondansetron | Cisplatin + tropisetron | Cisplatin + ramosetron |
|---|---|---|---|---|
| (n = 600) | (n = 200) | (n = 200) | (n = 200) | |
| Sex | ||||
| Male | 375 (62.5%) | 108 (54%) | 114 (57%) | 153 (76.5%) |
| Female | 225 (37.5%) | 92 (46%) | 86 (43%) | 47 (23.5%) |
| PS | ||||
| 0-1 | 554 (92.3%) | 185 (92.5%) | 189 (94.5%) | 180 (90%) |
| 2 | 46 (7.7%) | 15 (7.5%) | 11 (5.5%) | 20 (10%) |
| Weight (kg) | ||||
| mean | 63 | 62 | 65 | 61 |
| range | 42–90 | 45–86 | 42–90 | 45–78 |
| ≥70 | 535 (89.2%) | 174 (87%) | 185 (92.5%) | 176 (88.0%) |
| <70 | 65 (10.8%) | 26 (13%) | 15 (7.5%) | 24 (12%) |
| Baseline Ccr (mL/min) |
||||
| mean | 99.5 | 97.1 | 104.7 | 96.6 |
| range | 45.3–205.8 | 51.3–158.6 | 45.3–205.8 | 54.9–196.0 |
| Ccr during treatment (mL/min) |
||||
| mean | 86.3 | 92.4 | 93.8 | 72.8 |
| range | 42.2–181.6 | 48.9–147.4 | 42.2–181.6 | 43.5–121.1 |
| Cisplatin dose (mg) | ||||
| mean | 76.7 | 74 | 76 | 80 |
| range | 60–120 | 60–120 | 60–110 | 60–100 |
| Age (years) | ||||
| mean | 56 | 54 | 56 | 58 |
| range | 18–81 | 36–75 | 28–81 | 18–75 |
| ≥70 | 55 (9.2%) | 16 (8.0%) | 21 (10.5%) | 18 (9.0%) |
| <70 | 545 (90.8%) | 184 (92%) | 179 (89.5%) | 182 (91%) |
| Tumor type | ||||
| Esophageal | 87 (14.5%) | 10 (5.0%) | 15 (7.5%) | 62 (31%) |
| Lung | 164 (27.3%) | 36 (18%) | 41 (20.5%) | 87 (43.5%) |
| Gastric | 31 (5.2%) | 4 (2.0%) | 7 (3.5%) | 20 (10.0%) |
| Cervical | 87 (14.5%) | 32 (16.0%) | 47 (23.5%) | 8 (4.0%) |
| Endometrial | 27 (4.5%) | 20 (10.0%) | 4 (2.0%) | 3 (1.5%) |
| Bronchial | 173 (28.8%) | 99 (49.5%) | 47 (23.5%) | 27 (13.5%) |
| Others | 31 (5.2%) | 12 (6.0%) | 15 (7.5%) | 4 (2.0%) |